2. As of noon trading, Gilead ( GILD) is up $0.66 (1.25) to $53.83 on heavy volume Thus far, 8.4 million shares of Gilead exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $53.29-$54.19 after having opened the day at $54.12 as compared to the previous trading day's close of $53.17.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $77.5 billion and is part of the health care sector. The company has a P/E ratio of 31.0, above the S&P 500 P/E ratio of 17.7. Shares are up 38.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire